Match Document Document Title
US20110206765 Non-Typeable Haemophilus Influenzae Vaccines and Their Uses  
Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a...
US20110268797 MULTICOATED ALISKIREN FORMULATIONS  
An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers.
US20110045068 PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI  
The present invention relates to pharmaceutical formulations comprising a layer of compressed granules to facilitate the administration of oral PPI.
US20100297226 MULTIPLE UNIT PHARMACEUTICAL FORMULATION  
An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an...
US20140112989 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with...
US20140010874 Tamper Resistant Solid Oral Dosage Forms  
Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.
US20130059000 ORAL DELIVERY FOR HEMOGLOBIN BASED OXYGEN CARRIERS  
A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three...
US20110033528 STABILIZED PICOPLATIN ORAL DOSAGE FORM  
The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active metal salts. The core of the tablet is a...
US20120189693 ORAL DOSAGE FORMS  
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0...
US20140112986 PROLIPOSOMAL TESTOSTERONE FORMULATIONS  
Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder...
US20110287100 Galenic Formulations of Organic Compounds  
A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount...
US20140271856 ORALLY DISINTEGRABLE TABLETS  
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated...
US20110081412 ORALLY DISINTEGRABLE TABLETS  
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated...
US20110097401 METHODS FOR TREATING GASTROINTESTINAL DISORDERS  
Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the...
US20110076327 Herbal Pain Killer Compositions  
Disclosed are natural compositions including at least five core ingredients that provide pain relief without the side effects of synthetic pain relievers. Further provided are methods of making...
US20130108696 COATED CAPSULES AND TABLETS OF A FATTY ACID OIL MIXTURE  
Compositions comprising a fatty acid oil mixture and at least one free fatty acid in a coated capsule or a coated tablet form suitable for oral administration, and methods of use thereof, are...
US20130017261 USE OF LACTOBACILLUS FOR TREATMENT OF VIRUS INFECTIONS  
The present invention relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a pharmaceutical composition for the treatment and/or...
US20110091543 ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS  
Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed....
US20130243855 Modified coagulation factor IX polypeptides and use thereof for treatment  
Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral...
US20130164378 Special Prenatal Nutritional Supplement and Design Method Thereof  
A special prenatal nutritional supplement, characterized as containing active ingredients such as nutrients (including at least one or more vitamins), minerals, or a mixture of pharmaceutical and...
US20140065215 CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS OF NITAZOXANIDE  
Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is...
US20130236546 THYME/PRIMROSE OR IVY FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)  
The invention relates to an extract made of thyme (Thymus L.) in combination with primrose (Primula veris) or ivy (Hedera helix) for the prophylaxis and treatment of chronic obstructive pulmonary...
US20130224294 DRY PROCESSING OF ATAZANAVIR  
The invention relates to dry processes for producing oral dosage forms, more specifically tablets, comprising atazanavir and adhesion enhancers. The invention further relates to compacted...
US20130156855 ACNE TREATMENT  
One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine.
US20130251803 ONCE DAILY FORMULATION OF LACOSAMIDE  
A modified release formulation of lacosamide suitable for once-daily administration.
US20150050338 METHOD FOR TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME  
The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in...
US20130337055 COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSTICS FOR TREATMENT OF HEPATIC STEATOSIS ALONE OR IN COMBINATION WITH A HEPATITIS C VIRUS INFECTION  
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic...
US20110212176 CICLOPIROX AND CYTARABINE FOR THE TREATMENT OF LEUKEMIC DISORDERS  
The present application relates to compositions and methods for treating leukemic disorders. In particular, the present application relates to compositions and methods for treating the leukemic...
US20140294957 NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS  
The invention relates to niclosamide and derivates thereof, which effectively inhibit transcription of the S100A4 gene, resulting in inhibition and/or reduction of S100A4-induced cell motility,...
US20120263790 METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS  
Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia,...
US20110033533 GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS  
The present invention relates to a roller compacted solid oral dosage form comprising a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, wherein the...
US20140271859 MESALAMINE PHARMACEUTICAL COMPOSITION WITH MULTIPLE DOSAGE ELEMENTS FOR REDUCED DELIVERY VARIABILITY  
A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes...
US20120195964 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF  
The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the...
US20110104275 METHODS AND KITS FOR TREATING CLUSTER HEADACHE DISORDERS  
The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders.
US20110027360 PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS  
Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved...
US20130344149 Oral Dosage Forms for Modified Release Comprising Tasocitinib  
The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms.
US20140348920 Method of Treating Multiple Sclerosis  
The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering...
US20140030331 METHOD OF TREATING MULTIPLE SCLEROSIS  
The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequalae after multiple sclerosis attacks by administering...
US20150216821 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20150024046 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20140147499 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20140065217 MULTILAYER TABLET  
A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active...
US20140348918 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF ASTHMA  
The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.
US20110223248 METHODS AND COMPOSITIONS FOR TREATING LACTOSE INTOLERANCE  
The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and...
US20120258168 METHODS AND COMPOSITIONS TO PROMOTE OCULAR HEALTH  
Embodiments include a composition to promote ocular health and a method of treatment for a subject exposed to a source of oxidative or visual stress to the eye or having a degradation of the eye....
US20150104507 FORMULATION OF LACOSAMIDE  
A modified release formulation of lacosamide.
US20140065214 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE  
The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.
US20130243858 COMPOUND FORMULATIONS  
Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The...
US20110300213 Oral formulations of bipolar trans carotenoids  
The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a...
US20100226855 Rate-Controlled Oral Dosage Formulations  
The present invention relates to a drug delivery system, in which a drug containing core, either alone or coated with a rate controlling membrane system, is enveloped on its circumference by an...